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Abstract
X-linked myotubular myopathy (XLMTM) is a devastating, rare,
congenital myopathy caused by mutations in the MTM1 gene, result-
ing in a lack of or dysfunction of the enzyme myotubularin. This
leads to severe perinatal weakness and distinctive muscle pathology.
It was originally thought that XLMTM was related to developmental
arrest in myotube maturation; however, the generation and characteri-
zation of several animal models have significantly improved our un-
derstanding of clinical and pathological aspects of this disorder.
Myotubularin is now known to participate in numerous cellular pro-
cesses including endosomal trafficking, excitation-contraction cou-
pling, cytoskeletal organization, neuromuscular junction structure,
autophagy, and satellite cell proliferation and survival. The available
vertebrate models of XLMTM, which vary in severity from complete
absence to reduced functional levels of myotubularin, recapitulate
features of the human disease to a variable extent. Understanding
how pathological endpoints in animals with XLMTM translate to hu-
man patients will be essential to interpret preclinical treatment trials
and translate therapies into human clinical studies. This review sum-
marizes the published animal models of XLMTM, including those of
zebrafish, mice, and dogs, with a focus on their pathological features
as compared to those seen in human XLMTM patients.
Key Words: Congenital, Centronuclear, Hypotrophy, Myopathy,
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INTRODUCTION
X-linked myotubular myopathy (XLMTM) is a rare, dev-
astating, congenital myopathy that mainly affects infants and
children. XLMTM is caused by mutations in the MTM1 gene,
the result of which is a loss of function of the myotubularin pro-
tein that leads to severe perinatal weakness and distinctive mus-
cle pathology. While “myotubular myopathy” was first thought
to be related to a developmental arrest of myotube maturation
(1, 2), the generation and characterization of several animal
models over the past 15 years have led to significant advances
in our understanding of this disorder. Myotubularin is known to
participate in numerous cellular processes including endosomal
trafficking, excitation-contraction coupling (ECC), cytoskeletal
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organization, neuromuscular junction structure, autophagy, and
satellite cell proliferation and survival (3–7). Muscle-specific
knockdown of myotubularin in adult mice elicits similar pheno-
types, which indicates that myotubularin is essential for these
processes throughout life (8). The available vertebrate models of
XLMTM recapitulate features of the human disease to a variable
extent. Understanding how pathological endpoints in myotubu-
larin-deficient animals translate to human XLMTM patients will
be essential for interpretation of preclinical studies of potential
treatments and bridging therapies to the human clinical trial
stage. This review provides a summary of the published animal
models of myotubularin deficiency with a focus on comparing
the pathological features of these models with those seen in
human XLMTM patients. These pathological abnormalities are
summarized in the Table.
KNOWN FUNCTIONS OF MYOTUBULARIN
Myotubularin belongs to a family of 15 active and inac-
tive phosphatases that act on phosphoinositides, which are lipid
messengers that play important roles in membrane identity
and protein recruitment (9, 10). Through a common tyrosine
phosphatase-like domain, active myotubularin family members
dephosphorylate phosphatidylinositol 3-phosphate and phospha-
tidylinositol 3,5-bisphosphate, key regulators of membrane traf-
ficking and endocytosis (10, 11). The specificity of the different
myotubularins for particular organelles, suborganelle domains,
and particular membranes is a function of the unique combina-
tion of several shared domain structures that target the enzyme
to particular phosphatidylinositol pools (9, 11, 12). In animal
models, myotubularin appears to localize specifically to the sar-
colemma (plasma membrane) and sarcotubular membranes, and
regulates a range of functions within skeletal muscle cells (13,
14). The characterization of myotubularin localization in hu-
mans is not well studied due to the current lack of robust anti-
body-based tools. In cardiomyocytes, myotubularin has no
reported function, nor any clinical association with cardiac dis-
ease, despite its ubiquitous distribution (15). In skeletal muscle,
myotubularin is involved in the formation and maintenance of
the “triad,” the set of juxtaposed sarcoplasmic reticulum (SR)
and T-tubule structures responsible for mediating ECC (4, 5, 16,
17). The severely disrupted architecture of the sarcotubular
structures in XLMTM patients and myotubularin-deficient ani-
mal models leads to abnormal Ca2þ exchange at the sarcotubu-
lar junction and impaired ECC. Studies of contractile function
(4, 18) and myostatin inhibition therapy (19) in myotubularin-
deficient mice suggest that this impairment of ECC is a major
cause of weakness in XLMTM. Myotubularin also binds to des-
min and appears to control assembly of desmin intermediate fil-
aments (6); this interaction may contribute to the organelle mis-
localization observed in myotubularin-deficient muscle fibers.
Additionally, myotubularin deficiency produces abnormalities
of the neuromuscular junction (3) and satellite cell numbers (8,
20, 21), which, in mouse models, likely contributes to progres-
sive disease pathology and contractile dysfunction. Abnormali-
ties in the apoptotic, AKT/mTOR and ubiquitin-proteasome
pathways (8, 22, 23), have also been reported in multiple models
of myotubularin deficiency; these may further exacerbate the
disease pathology and progression.
PATHOLOGICAL FINDINGS IN HUMAN XLMTM
The diagnosis of XLMTM is often strongly suggested by
the histopathology observed in a muscle biopsy. The character-
istic light microscopic changes of XLMTM in humans often
include: (1) myofiber hypotrophy (smallness), particularly of
type 1 fibers, (2) a variable number of large-appearing, central
myofiber nuclei spaced at regular intervals along the longitudi-
nal axis, (3) central aggregations of organelles including mito-
chondria, lysosomes, and SR, (4) pale peripheral halos seen
with staining for oxidative enzymes (Fig. 1), and (5) perinu-
clear vacuole-like areas (24). The central nuclei occur in both
fiber types, and their frequencies range from as low as 5% (25)
to greater than 50% (26). Central nuclei are often more com-
mon in myofibers expressing slow myosin and they can occur
in fibers without developmental or fetal myosin, indicating
TABLE. Comparison of Pathological Abnormalities in Various Myotubularin-Deficient Vertebrate Models and the Human Disease
Species Model Disability Nuclear Placement Organelle Localization Neuromuscular
Junctions
Necklace Fibers
Human N/A Severe Central Central aggregates with
peripheral halos
Abnormal Present, especially in mild
cases or carriers
Zebrafish Morpholino
knockdown
Severe Central Central aggregates Abnormal Not assessed
Mouse Mtm1 KO Severe Internal Subsarcolemmal aggregates Abnormal None
Mtm1 p.R69C Moderate Internal Subsarcolemmal aggregates Abnormal None
Mtm1gt/y Mild Internal Peripheral aggregates Not assessed Not assessed
Canine Labrador XLMTM Moderate
to severe
Internal Peripheral and central
aggregates, sometimes
with halos
Not assessed Frequent
KO, knockout; N/A not applicable; XLMTM, X-linked myotubular myopathy.
Note that fiber size is consistently small and sarcotubular disorganization is consistently disorganized in all models of myotubularin deficiency that have been evaluated for these
features.
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that they have matured at least in terms of myosin expression.
All of these features are often seen in human XLMTM patient
muscle at birth (26). Satellite cell numbers may be decreased
in human XLMTM biopsies that have been taken as early as
30 weeks of gestational age (26); however, quantitation of sat-
ellite cells in human muscle can be difficult because factors
such as muscle sampled and fiber typing have to be taken into
account (26). Necrosis, peri- and endomysial fibrosis, and in-
flammation are not features of XLMTM in any species. Ultra-
structurally, there is disorganization of the sarcotubular system
that produces a dramatic decrease in the number and mis-
localization of triads (Fig. 2) (5). Collections of dark tubules,
probably of SR origin, can occur (Fig. 2); and other features
can include marked absence or disruption of myofibrils and
cytoplasmic bodies. Of note, the histopathologic features of
XLMTM do not appear to predict clinical severity. Specifi-
cally, no relationship has been found between the number of
centrally nucleated fibers and clinical outcomes. It has been re-
ported that poorer outcomes have been observed in patients
with smaller myofiber size at biopsy (25). Anecdotally, some
XLMTM patients with comparatively mild phenotypes show
organelle mislocalization in only a small proportion of fibers
(Supplementary Data 1). Longitudinal studies of pathological
progression in the same human patients have only rarely been
reported (27, 28), and a comparison of biopsy and autopsy
specimens during our review identified more uniform myofiber
smallness in autopsy specimens from XLMTM patients in com-
parison to the fiber size variation (including numerous hypotro-
phic fibers) that is typically seen on diagnostic biopsies.
Genetic confirmation of a mutation in the MTM1 gene is
essential for the definitive diagnosis of XLMTM. While the
findings described here at the light and electron microscopic
level strongly suggest XLMTM, some of these findings may
be seen in other severe forms of centronuclear myopathy
(CNM) and in congenital myotonic dystrophy (CDM) (24, 29,
30). Cases of CNM with severe clinical presentations due to
mutations in DMN2, BIN1, and RYR1 may show pathological
findings similar to those in XLMTM, including small myofiber
size, central nucleation, and central aggregates of organelles
with peripheral halos. These pathological features are more
commonly associated with mutations in MTM1, however, than
mutations in DMN2, BIN1, and RYR1. With respect to CDM,
the pathological features encountered depend on the patient´s
age and tend to be more severe in early cases. In neonatal
cases, myofibers are small, nuclei are central, and oxidative en-
zyme staining may reveal fibers with a pale peripheral halo
and dark central aggregates of organelles. Slow fibers are less
frequent in congenital CDM biopsies, in comparison to early
XLMTM biopsies (31). No ring fibers or sarcoplasmic masses
(areas of abundant acid-phosphatase positive material) are ob-
vious at birth, but these may appear by 12 months of age and
these features are not seen in XLMTM. Internal nuclei are in-
creased and prominent, often occurring in long chains. Elec-
tron microscopy of CDM biopsies taken in the first year of life
show a peripheral zone containing glycogen and myofila-
ments but lacking organized myofibrils and mitochondria,
which contrasts with the central organelle aggregation and
loss of sarcotubular organization that is seen in XLMTM.
Antibodies against muscleblind-like 1 (MNBL1) are helpful
for distinguishing CDM cases from CNMs, including myotub-
ular myopathy, as the latter are negative, while CDM biopsies
show anti-MBNL1 positively stained nuclear foci (32–34).
Most women carrying mutations in MTM1 (XLMTM
carriers) are asymptomatic (35). There are reports, however, of
FIGURE 1. Pathological findings in murine, canine, and human
X-linked myotubular myopathy (XLMTM) by brightfield micros-
copy. Skeletal muscle from anMtm1 knockout mouse at 43 days
of life (mid-stage) are shown in comparison to an autopsy speci-
men from an 18-week-old (end-stage) canine with XLMTM and
a diagnostic biopsy of a 2-month-old boy with XLMTM. Hema-
toxylin and eosin (H&E) staining reveals abnormal fiber size vari-
ation and the extent of central or internal nucleation in each af-
fected species. In addition to the hypotrophy of some fibers seen
at all disease stages, XLMTM shows marked atrophy of essen-
tially all fibers in the terminal stage; therefore, the apparent dif-
ference in myofiber size between the murine (mid-stage) and
canine models (end-stage) shown likely relates to disease stage.
The percentage of centrally nucleated fibers can vary markedly
among patients (H&E inset). Stains for reduced nicotinamide
adenine dinucleotide (NADH, also known as NADH-TR) and pe-
riodic acid-Schiff (PAS) stain illustrate the patterns of organelle
(mitochondrial/sarcotubular) and glycogen mislocalization, re-
spectively, with pale peripheral halos in the human case but
dark peripheral staining in the dog and mouse. Mouse tissue
typically shows subsarcolemmal aggregation of mitochondria
whereas true “necklace fibers” (arrows) can be seen in canine
and some human (NADH inset) patient biopsies, as well as in
rare fibers in the mouse. Scale bar¼ 40 mm.
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XLMTM carriers with myopathic symptoms and pathology con-
sistent with CNM. The clinical severity of these symptomatic
XLMTM carriers ranges broadly from severe neonatal weakness
(extremely rare) to mild/moderate weakness with a normal life-
span. This broad range of symptomatic severities probably re-
flects skewed inactivation of the X chromosome (lyonization),
where symptomatic XLMTM carriers have more lyonization of
the normal MTM1 allele than those carriers with no symptoms
(35–38). The pathology in the reported cases is variable (Supple
mentary Data 1), but (in contrast to XLMTM male patients) the
degree of XLMTM pathology does tend to correlate with the
level of clinical severity. Biopsy findings in XLMTM carriers
with symptoms during infancy were very similar to those seen
in male patients, including myofiber smallness, numerous cen-
trally nucleated fibers, type 1 fiber predominance, central
aggregations of organelles, and peripheral halos (36, 39). In ad-
dition, necklace fibers with a basophilic loop a few microns be-
neath the sarcolemma, and associated with internal nuclei, can
be a feature of female carriers and milder cases, but may be less
common in severe cases (40). XLMTM carriers identified dur-
ing adulthood display slightly different muscle pathology to
those identified in infancy. While carriers with infantile onset
tend to have severe disease and pathology similar to affected
XLMTM boys, those with later onset display pathological find-
ings including increased fiber size variation (due to the presence
of large and small fibers), numerous fibers containing internal
nuclei (with a subpopulation of centrally nucleated fibers), and
occasional perinuclear vacuole-like areas (37, 38). As such, the
pathology of these adult symptomatic XLMTM carriers is more
similar to non-XLMTM cases of CNM; this should be a diag-
nostic consideration when encountering CNM in adult female
patients.
ZEBRAFISH MODEL OF XLMTM
The zebrafish knockdown model of myotubularin defi-
ciency was created using antisense morpholinos to generate
embryos with reduced myotubularin protein expression (5).
Similar to human XLMTM patients, the zebrafish knockdown
model exhibits severe impairment of motor function, muscle
fiber hypotrophy, and large-appearing, abnormally located
nuclei (Fig. 3). Phenotypic effects are evident very early in
the development process. By 24 hours postfertilization, em-
bryos have abnormal dorsal curvature through the back and
tail and significantly fewer spontaneous muscle contractions.
By 72 hours postfertilization, embryos typically have thin-
ning of the muscle compartment and bent and/or foreshort-
ened tails that correlate with markedly decreased ability to
hatch from their chorions, poor touch-evoked escape re-
sponses, and diminished swimming capacity.
Pathologically, the zebrafish knockdown model displays
findings similar to those seen in human XLMTM patients, in-
cluding myofiber smallness, centrally nucleated fibers, and
mislocalization of organelles (5). There is also ultrastructural
disarray of the sarcotubular system that is similar to that
seen in human myotubularin deficiency (Fig. 3) (5). The neu-
romuscular junction in myotubularin-deficient zebrafish, as
observed using a-bungarotoxin staining, shows normal-appear-
ing neuronal input but abnormal organization, which is re-
flected as sparse staining that is generally located in the middle
of the myofiber (41). Treatment with an acetylcholinesterase
inhibitor strongly improved deficits in spontaneous coiling and
touch-evoked escape behaviors, supporting the association be-
tween myotubularin support of membrane trafficking and
regulation of acetylcholine receptors (42, 43). A similar, albeit
less dramatic, response to acetyl cholinesterase inhibitors has
also been observed in human cases of XLMTM (41).
Ultrastructural analysis of morpholino-treated zebrafish
muscle tissue shows grossly aberrant SR and T-tubule networks
(5). SR networks are irregular, disorganized, and often randomly
interspersed throughout the sarcomere. Abnormalities in T-
tubule structures range from mild changes in triad electron den-
sity to fibers with nearly unrecognizable SR/triad regions. These
FIGURE 2. Ultrastructural findings in human X-linkedmyotubular
myopathy (XLMTM). (A) Low-power ultrastructural evaluations
of XLMTM muscle reveal centrally located nuclei and central ag-
gregates of organelles including mitochondria (left) and areas
with only nuclei and glycogen (right). (B, C) Higher power
shows organizational abnormalities of the sarcotubular system.
Stacks of tubules (probably originating from triads) can be seen in
a variety of configurations in the intermyofibrillar space, some of
which contain osmiophilic material (B). There is also a lack of
well-defined triad structures (white arrows) in XLMTM muscle in
contrast to what is seen in normal muscle (C).
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alterations in the T-tubule and SR networks, which resemble hu-
man pathology, are related to functional impairments in ECC.
MOUSE MODELS OF XLMTM
The first animal model of XLMTM, the Mtm1 knock-
out (KO) mouse (also called the Mtm1d4 mouse), was pro-
duced through a large deletion in exon 4 of Mtm1(44). Mtm1
KO mice show weakness starting at approximately 3 weeks
of life that progresses to death in a fairly uniform timescale
(usually around 5–7 weeks of life, range 4–14 weeks, depend-
ing on the background strain) (19, 44). Abnormal nuclear
placement is observed in Mtm1 KO muscle at a lower per-
centage of muscle fibers than is usually observed in human
XLMTM patients, and the placement of these nuclei is typi-
cally eccentric rather than central (Fig. 1). A similar “inter-
nally nucleated fiber” phenotype is observed in other murine
and canine models of myotubularin deficiency. The number
of internally nucleated fibers is essentially normal during the
perinatal period in Mtm1 KO mice and this gradually
increases with age to between 5% and 45% of fibers at end-
stage disease. Mtm1 KO mice show marked myofiber hypo-
trophy in at least a subset of fibers (including both oxidative
and glycolytic fibers), and this is most apparent after 3 weeks
of age when fibers are mature. At this stage of disease, fiber
smallness is most consistent with a hypotrophic process
rather than an atrophic process, based on fiber shape at the
light microscopic level and the absence of redundant basal
lamina at the ultrastructural level. Organelle mislocalization
occurs in myofibers of Mtm1 KO mice, with fibers that con-
tain perinuclear central accumulation of mitochondria, but
the pattern is most frequently that of a peripheral ring of mito-
chondria at the sarcolemma and markedly decreased numbers
of mitochondria in the central areas of the fiber (and thus
somewhat distinct from the patterns seen in canines and hu-
mans) (Fig. 1) (4, 19, 44). Sarcotubular elements are also ag-
gregated in the same locations as the mitochondria, which
can be clearly visualized on immunostaining for the ryano-
dine receptor (RYR1) and the dihydropyridine receptor a
(DHPR-a) (Fig. 4) (4). By electron microscopy, there is dis-
organization of the sarcotubular system, with presence of lon-
gitudinal tubules (L-tubules) and a decrease in triad number
similar to that seen in human XLMTM (4, 5, 18). Organelle
mislocalization and triad disorganization are the earliest de-
scribed pathological signs of the disease in these mice, and
progress over time (4).
The availability of the Mtm1 KO model has allowed sys-
tematic evaluations of disease pathology in the context of dis-
ease progression and the spectrum of disease severity among
several different muscles. Progression of disease in Mtm1 KO
mice generally correlates with increasing numbers of myofib-
ers displaying characteristic XLMTM-like pathology: myo-
fiber smallness and organelle mislocalization. These features
are found in nearly all fibers by the time the mice are killed
due to symptomatic severity between 4 and 14 weeks of life
(19, 44). Myofiber smallness at late stages of disease is proba-
bly caused by a combination of hypotrophy and atrophy, as av-
erage fiber size decreases during terminal phases of disease.
As noted above, the number of fibers with internal nuclei also
increases with age. Approximately 5% to 45% of fibers have
internal nuclei in most Mtm1 KO mice by the end of the dis-
ease course, but this percentage varies depending on the mus-
cle in the body and strain background (4, 13). The number of
muscle satellite cells in Mtm1 KO mice decreases with age to
approximately 30% of wild-type values at late disease stages
(20). Neuromuscular junctions are enlarged and less complex
than normal at the ultrastructural level (3). Whole-muscle
ex vivo contractile function in extensor digitorum longus and
FIGURE 3. Pathological findings in human and zebrafish X-
linked myotubular myopathy (XLMTM). (A) Hematoxylin and
eosin (H&E)-stained longitudinal myofibers from myotubular
myopathy (MTM) and age-matched control (CTL) human
muscle biopsies. Arrows indicate abnormal nuclei. (B) H&E-
stained longitudinal myofibers from zebrafish control (CTL
MO) and myotubularin morphant (MTM MO) 72-hour-post-
fertilization embryos. Myonuclei are abnormally rounded (ar-
rows), and there is increased space between fibers in the mor-
phant (*). (C) Toluidine blue-stained semi-thin sections from
72-hour-postfertilization morphants. Myonuclei from myotu-
bularin morphants are large, abnormally rounded, and contain
discrete nucleoli (arrows). Sarcomeric units are normal in ap-
pearance. Scale bar ¼ 20 mm. Reproduced with permission
from Dowling JJ, Vreede AP, Low SE et al. Loss of myotubularin
function results in T-tubule disorganization in zebrafish and
human myotubular myopathy. PLoS Genet 2009;5:e100372.
CopyrightVC 2009 Dowling et al.
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soleus muscles of Mtm1 KO mice showed impaired contractile
force, with slightly better performance seen in the predomi-
nantly oxidative soleus muscle than in the predominantly gly-
colytic extensor digitorum longus muscle (18). In contrast,
skinned fiber preparations using Mtm1 KO myofibers showed
equivalent function between slow and fast myofibers, suggest-
ing that the better performance in oxidative muscles noted
above was due to a factor (perhaps mitochondria) that was re-
moved or destroyed during the chemical skinning process.
Mtm1 KO mice are the most frequently used model for
preclinical treatment trials, and a variety of pathological recov-
ery patterns have been seen. An early study using intramuscu-
lar injection of adeno-associated virus (AAV) carrying the
Mtm1 coding sequence (AAV8-Mtm1) showed complete cor-
rection of XLMTM pathology at the light microscopic level in
the injected limbs (13). Correction of pathology was seen
across all muscle groups, and the lifespan of the mice was ex-
tended beyond 6 months after a single dose of the vector at 9
weeks of age (45). Concurrently, a targeted enzyme replace-
ment agent (3E10Fv-MTM1) was developed that combined
enzymatically active myotubularin with an antibody fragment
that improved distribution to muscle. Proof-of-concept pilot
studies using local injections of a nonoptimized 3E10Fv-
MTM1 dose over 2 weeks showed improvements in single-
muscle strength and sarcotubular ultrastructural organization,
whereas XLMTM pathology at the light microscopic level was
unchanged (18). In contrast, a trial of the myostatin inhibitor,
ActRIIB-mFc, produced dramatic improvement of glycolytic
fiber size but with minimal benefits to lifespan or strength
(19). Because ActRIIB-mFc provided a means of mitigating
myofiber hypotrophy without affecting the other pathological
features of myotubularin deficiency, these studies suggest that
abnormalities of organelle localization and/or ECC comprise
the predominant cause(s) of weakness in these mice. This con-
cept is further supported by the comparison of functional stud-
ies using whole-muscle versus skinned fiber preparations,
which reveal a large component of contractile deficit that is
only apparent when membranous structures are intact (18).
While this component of weakness may be due to abnormali-
ties in the sarcolemma, mitochondria, or sarcotubular system,
the known abnormalities of sarcotubular organization and cal-
cium handling suggest that ECC impairment is a major factor.
TISSUE-SPECIFICMTM1 KO MICE
There have been several studies to induce myotubularin
deficiency to specific tissues and/or time periods. Conditional
Mtm1 KO mice that were myotubularin deficient only in skele-
tal muscle (using a transgenic line that expresses Cre recombi-
nase under the skeletal muscle a-actin promoter) showed a
phenotype that was indistinguishable from Mtm1 KO mice
(44). In contrast, conditional Mtm1 KO mice that were myotu-
bularin deficient in the central nervous system but not skeletal
muscle (using a transgenic line expressing Cre recombinase
under the neuron-specific enolase promoter) did not show any
obvious clinical or pathological phenotype. To study the im-
pact of myotubularin deficiency on adult muscle, a recombi-
nant AAV that expresses Cre recombinase under the muscle-
FIGURE 4. Immunofluorescence patterns of organelle mislocali-
zation in X-linked myotubular myopathy (XLMTM). Abnormal-
ities of organelle localization are seen to varying degrees in the
mouse and dog models using antibodies against the ryanodine
receptor (RYR1) and the dihydropyridine receptor a (DHPR-a),
which are found on the sarcoplasmic reticulum and T-tubules,
respectively. Staining for RYR1 displays varying degrees of ab-
normal organelle aggregation in each model, although this is
more difficult to appreciate in comparison to reduced nicotin-
amide adenine dinucleotide (NADH-TR) staining. Staining for
DHPR-a shows a similar pattern of mislocalization in murine and
canine XLMTM, but organelle mislocalization cannot be clearly
visualized on human XLMTM tissue. Immunostaining for elec-
tron transport chain complex IV shows clear mitochondrial mis-
localization in mouse, canine, and human XLMTM. Staining of
human muscle biopsy tissue without pathological findings
(“Normal Human”) displays even intracellular staining for all 3
antigens. Staining for RYR1, DHPR-a, and cytochrome oxidase
(COX) are shown on the green channel, with dystrophin immu-
nostaining shown on the red channel to highlight myofiber
edges. Scale bar¼ 50 mm.
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specific desmin promoter was injected locally into the muscle
of adult conditional Mtm1 KO mice (8). Myotubularin defi-
ciency in these muscles produced weakness and pathology that
was strikingly similar to the effects of germline mutations in
Mtm1, including progressive decreases in myofiber size, mis-
localization of organelles, increases in the number of internally
nucleated fibers, and abnormal sarcotubular morphology on
electron microscopy. The number of satellite cells progres-
sively decreased in myotubularin-deficient adult muscles, and
abnormalities in proteins related to Akt signaling, neuromuscu-
lar transmission, and autophagy were also observed.
MTM1 P.R69C MICE
The Mtm1 p.R69C mouse was designed to produce a
less severe myotubularin deficiency phenotype by “knocking
in” the c.205C>T mutation that had been found in several hu-
man XLMTM patients who survived past infancy (46). As
predicted, Mtm1 p.R69C mice have greater strength than
Mtm1 KO mice, and lifespans often exceeding 1 year. Similar
to the pathology seen in Mtm1 KO mice, affected myofibers
display hypotrophy and mislocalization of organelles (as de-
scribed above). As observed in the Mtm1 KO and canine
XLMTM models, there is abnormal localization of nuclei,
which are usually eccentric rather than central. This pattern is
slightly different from that seen in human XLMTM, where
nuclear placement tends to be central rather than eccentric.
The number of internally nucleated fibers may only be mildly
increased (21, 46). Neuromuscular junctions are enlarged and
have less complex junctional folds than are seen in wild-type
mice (3). Satellite cell depletion is noted at late stages of dis-
ease in these mice (21). It should be noted that the Mtm1
p.R69C mutation functions as a splice site mutation leading
to the expression of only a very small amount of full-length
mutant myotubularin transcript, and a similar impact on splic-
ing has been observed in human tissue harboring the MTM1
p.R69C mutation (46). This suggests that induction of very
small amounts of myotubularin may produce substantial clin-
ical benefits in the myotubularin-null state.
Mtm1 p.R69C mice have been used in several published
trials of potential treatments for XLMTM. Pyridostigmine (an
acetylcholinesterase inhibitor that improves neuromuscular
transmission) produced improvements in grip strength and en-
durance (3) as has been found in some human cases (41), but
evaluations of treatment effects on histopathology were not
performed. Localized wild-type myoblast transplantation into
the gastrocnemius muscle of Mtm1 p.R69C mice produced in-
creases in muscle mass and evoked muscle action potentials,
but increases in fiber size were not observed and other patho-
logical features were not assessed (47). Additionally, a study
of myostatin inhibition using ActRIIB-mFc in Mtm1 p.R69C
mice identified some muscle-specific phenotypes in these
mice. Treated mice developed hypertrophy of glycolytic myo-
fibers only in the gastrocnemius muscle, without apparent ef-
fect in other muscles such as the quadriceps or triceps (21).
This was markedly different from the effects observed in the
Mtm1 KO model using the same agent, which produced signif-
icant hypertrophy in all of these major muscles (19). Subse-
quent studies identified differences between the Mtm1 p.R69C
quadriceps and gastrocnemius muscles with respect to satellite
cell behavior and hypertrophic signaling that may have been
associated with differential treatment responses in these ani-
mals (21). While the precise mechanism(s) responsible for
these different responses remains unclear, the results estab-
lished that treatment studies using the mouse models should be
cautiously designed, and analysis of various muscle groups is
advisable.
MTM1gt/yMICE
An Mtm1 mutant mouse with a truncating mutation in
exon 1 of Mtm1 has been described in a single publication
(23). The Mtm1gt/y mice are similar in weight to wild-type an-
imals until approximately 4 weeks of age, and, therefore,
have a less severe phenotype than Mtm1 KO mice. Muscle
pathology in Mtm1gt/y appears similar to other myotubularin-
deficient mice, including myofiber smallness, subsarcolem-
mal organelle localization, mild increases in the number of
internal nuclei, and ultrastructural sarcotubular disorganiza-
tion. A blockage of a late stage of autophagy was detected in
these mice, resulting in protein aggregates that are positive
for ubiquitin and p62. Such protein inclusions have not been
reported in other models of XLMTM, although other studies
in Mtm1 KO mice showed dysregulation of autophagy and
ubiquitin-proteasome pathways that resulted in ultrastructur-
ally abnormal autophagosomes (8, 22). Analysis of Mtm1gt/y
mice also revealed abnormalities of mitochondrial structure
including mitochondria with fewer decondensed and swollen
cristae (23), which can be seen to some extent across all
XLMTM models studied. The degree to which mitochondrial
structural abnormalities are due to primary mitochondrial dys-
function versus secondary effects is currently unclear.
CANINE XLMTM
X-linked myotubular myopathy in dogs was discovered
as a naturally occurring disease in several related litters of Lab-
rador Retriever (MTM1 p.N155K) puppies (14). This led to the
establishment of a XLMTM canine colony that has been in-
strumental for preclinical studies in this canine model.
XLMTM Labradors, and subsequent generations bred onto a
beagle background, appear phenotypically normal at birth, but
by 8 weeks of age, they begin to display a characteristic “slack
jaw” appearance. Shortly thereafter, XLMTM puppies display
subtle hind limb muscle weakness, gait abnormalities, and re-
duced physical activity. Ultimately, these clinical impairments
progress until death becomes necessary between 15 and 26
weeks of age (14). Affected dogs exhibit muscle pathology
similar to the Mtm1 KO and Mtm1 p.R69C murine models, in-
cluding myofiber hypotrophy (of both slow and fast fibers),
mild-to-moderate increases in the number of internally nucle-
ated fibers, mislocalization of organelles, and disorganization
of the sarcotubular system at the ultrastructural level (14, 45).
All of these features are present in a subpopulation of fibers
at 10 weeks of life, and they tend to affect greater numbers of
fibers as the disease progresses. One remarkable pathologic
feature of canine XLMTM is a pattern of organelle mislocali-
zation distinctively different from both murine and human
XLMTM. Whereas the pattern of organelle/mitochondrial
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mislocalization in humans tends to be a central aggregation,
and in murine models tends to be subsarcolemmal (necklace-
like), XLMTM Labradors and “Lab-beagles” show a combina-
tion of central organelle aggregation, true necklace fibers, and
fibers with necklace-like subsarcolemmal organelle aggregates
(14, 45). In cases where these aggregates are associated with
internalized nuclei along the same line, they can be considered
true “necklace fibers” that have been reported in a range of
CNMs. Similar to that demonstrated in Mtm1 KO mice, these
aggregates of mislocalized organelles stain for markers of mi-
tochondria (complex IV), T-tubules (DHPR-a), and SR
(RYR1) (Fig. 4) (14). While the varying patterns of organelle
mislocalization across different myotubularin-deficient models
likely represent different aspects of a similar pathogenic pro-
cess, it is important to recognize this spectrum of patterns
when considering how best to evaluate and quantify pathologi-
cal features. A pilot study assessing satellite cell number in the
vastus lateralis and gastrocnemius muscles of XLMTM Lab-
beagles comparing satellite cell numbers at 10 and 17 weeks of
age did not show satellite cell depletion (unpublished). It
should also be noted that canine XLMTM carriers do not show
weakness or any sign of MTM pathology in any of the studies
performed thus far, despite extensive evaluation. Canine
XLMTM has also recently been reported in Rottweiler dogs
(MTM1 p.Q384P) (48), which showed extensive similarities to
the MTM1 p.N155K dogs, both in terms of pathological find-
ings and clinical features.
The canine MTM1 p.N155K XLMTM model has been
used to test gene therapy for XLMTM (AAV8-MTM1—a
recombinant AAV8 vector, carrying the canine MTM1 cDNA
under control of the desmin promoter) in a pilot study (45).
Intramuscular injections of AAV8-MTM1 in hind limb cra-
nial tibialis muscles demonstrated dramatic and rapid im-
provements in strength and a concomitant reversal of
XLMTM pathology (including resolution of myofiber hypo-
trophy, organelle mislocalization, number of centrally nucle-
ated fibers, and sarcotubular organization) in the injected
limb in comparison with contralateral saline-injected limbs
(45). Follow-up studies using systemic AAV8-MTM1 admin-
istered intravenously produced similar histopathologic and
functional improvements in all muscles sampled for at least 1
year after a single dose (45), and further systemic dosing and
long-term follow-on studies are in progress. Based on these
encouraging results, clinical studies utilizing gene therapy are
now planned.
CONCLUSION
XLMTM is a severe congenital myopathy with charac-
teristic pathological findings in most cases, including myofiber
hypotrophy, centrally nucleated myofibers, and mislocalization
of organelles. When comparing myotubularin-deficient fish,
mice, and dogs to human patients, there are many similarities
in pathology, but there are also some differences in how these
abnormalities manifest (Table). Such variation needs to be ac-
counted for when designing strategies for the quantitation of
pathological findings in XLMTM, and our group is currently
developing techniques that address these issues. As therapeutic
development progresses from nonclinical to clinical studies in
XLMTM, an understanding of the impact of myotubularin de-
ficiency in each species is essential for the appropriate design
of pathological endpoints using human muscle tissue, and in-
deed for understanding the translatability of findings in an ani-
mal model to humans.
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